• 基本信息
    导师姓名： 王玉刚 学科代码： 100201
    性别： 男 学科名称： 内科学
    培养单位： 附属同仁医院 三级学科 消化系病
    导师类型： 博士生导师 专业领域名称： 内科学 专业学位
    联系方式： 18121226113 专业领域代码： 105101
    邮编： 200336 邮箱地址： wang_yugang@sina.com
  • 研究方向 (点击浏览详细信息)
  • 社会任职
     
    中国医促会消化病分会委员
    上海市医学会消化病分会委员
    上海市医学会消化病分会肠道微生物及HP学组委员
    中国生理学会消化与营养专业委员会委员
    上海市医学会肝病分会自身免疫性肝病学组委员
  • 科研项目
    项目编号项目名称课题来源起止年月批准经费承担职责
    23ZR1458300基于模拟肿瘤微环境刺激的巨噬细胞外泌体构建高效 靶向及协同抗肿瘤载药平台的研究上海市科委自然基金 2023-04~2026-03 20万元  课题负责人
    8187100566低pH环境通过下调外泌体CD280强化肿瘤细胞内吞促进Ori-AlPcS-Exo发挥多级靶向抗胃癌的研究国家自然科学基金面上项目 2019-01~2022-12 54万元  课题负责人
    ZK2015A24上海市医学重点专科A类上海市卫计委 2015-12~2018-12 100万元  课题负责人
    81472242基于HATs靶点的天然小分子化合物LXD-070抗胃癌机制研究国家自然科学基金面上项目 2015-01~2018-12 70万元  课题负责人
    YXMZK003医学名专科-消化内科上海市长宁区卫计委 2015-01~2018-12 10万元  课题负责人
    2015C01长宁区创新团队 上海市长宁区科委 2014-12~2017-12 50万元  课题负责人
    14ZR1431600以HATs为靶点抑制胃癌的天然小分子化合物的筛选及机制研究 上海科委自然基金 2014-08~2017-08 30万元  课题负责人
    ZK2012A05上海市医学重点专科A类 上海市卫计委 2012-10~2015-10 100万元  课题负责人
    2011QZB02慢性肝病综合诊治上海市长宁区卫计委 2012-01~2015-12 10万元  课题负责人
    2011R01长宁区创新孵化团队上海市长宁区科委 2011-01~2014-12 15万元  课题负责人
  • 学术论文
    作者论文标题期刊名出版年卷期页码
    Ni J, Guan C, Liu H, Huang X, Yue J, Xiang H, Jiang Z, Tao Y, Cao W, Liu J, Wang Z,, Wu X.   Ubc13 Promotes K63-Linked Polyubiquitination of NLRP3 to Activate Inflammasome.  J Immunol.  2021  2021 May 15;206(10):2376-2385. 
    Xu X, Li N,, Yu J, Mi J.   Calcium channel TRPV6 promotes breast cancer metastasis by NFATC2IP.   Cancer Lett.  2021  2021 Oct 28;519:150-160. 
    Gan G, Shi Z, Liu D, Zhang S, Zhu H,, Mi J.   3-hydroxyanthranic acid increases the sensitivity of hepatocellular carcinoma to sorafenib by decreasing tumor cell stemness.  Cell Death Discov.  2021  2021 Jul 6;7(1):173. 
    , Wang T, Ding M, Xiang SH, Shi M, Zhai B.  FOXD1-AS1 regulates FOXD1 translation and promotes gastric cancer progression and chemoresistance by activating the PI3K/AKT/mTOR pathway.  Mol Oncol  2021  2021 Jan;15(1):299-316. 
    , Wang T, Shi M, Zhai B.  Long noncoding RNA EPB41L4A-AS2 inhibits hepatocellular carcinoma development by sponging miR-301a-5p and targeting FOXL1.  J Exp Clin Cancer Res.  2019  38(1):153.  
    , Zheng DH, Shi M, Xu XM.  T cell dysfunction in chronic hepatitis B infection and liver cancer: evidence from transcriptome analysis.  J Med Genet.  2019  56(1):22-28. 
    Wu Q, Shi M, Meng W,, Hui P, Ma J.  Long noncoding RNA FOXD3-AS1 promotes colon adenocarcinoma progression and functions as a competing endogenous RNA to regulate SIRT1 by sponging miR-135a-5p.  J Cell Physiol.   2019  234(12):21889-21902.  
    , Wang T, Ding M, Xiang SH, Shi M, Zhai B.  hsa_circ_0091570 acts as a ceRNA to suppress hepatocellular cancer progression by sponging hsa-miR-1307.  Cancer Lett.   2019  2019 Sep 28;460:128-138.  
    Shi M, Jiang Y, Yang L, Yan S,, Lu XJ.   Decreased levels of serum exosomal miR-638 predict poor prognosis in hepatocellular carcinoma.   J Cell Biochem  2018  119(6):4711-4716. 
    Wu Q, Xiang S, Ma J, Hui P, Wang T, Meng W, Shi M,  Long non-coding RNA CASC15 regulates gastric cancer cell proliferation,migration and epithelial mesenchymal transition by targeting CDKN1A and ZEB1.   Mol Oncol.   2018  12(6):799-813.  
    Xu L, Gong C, Li G, Wei J, Wang T, Meng W, Shi M,  Ebselen suppresses inflammation induced by Helicobacter?pylori lipopolysaccharide via the p38 mitogen-activated protein kinase signaling pathway.   Mol Med Rep   2018  17(5):6847-6851.  
    Shi M, Zhang XY, Yu H, Xiang SH, Xu L, Wei J, Wu Q, Jia R,, Lu XJ.  DDX11-AS1 as potential therapy targets for human hepatocellular carcinoma.  Oncotarget  2017  8(27):44195-44202.  
    Deng Y, Chen C, Yu H, Diao H, Shi C,, Li G, Shi M.   Oridonin ameliorates lipopolysaccharide/D-galactosamine-induced acute liver injury in mice via inhibition of apoptosis.   Am J Transl Res.   2017  9(9):4271-4279  
    Xu L, Dai W, Li J, He L, Wang F, Xia Y, Chen K, Li S, Liu T, Lu J, Zhou Y,, Guo C.   Methylation-regulated miR-124-1 suppresses tumorigenesis in hepatocellular carcinoma by targeting CASC3.  Oncotarget.  2016  7(18): 26027-26041. 
    Xue HY, Zhang X,, Xiaojie L, Dai WJ, Xu Y.   In vivo gene therapy potentials of CRISPR-Cas9.  Gene Ther.   2016  23(7):557-9. 
    Yu CB, Zhu LY,, Li F, Zhang XY, Dai WJ. Systemic transcriptome analysis of hepatocellular carcinoma.  Systemic transcriptome analysis of hepatocellular carcinoma.  Tumour Biol.  2016  26: 1-9. 
    Shi M, Lu XJ, Zhang J, Diao H, Li G, Xu L, Wang T, Wei J, Meng W, Ma JL, Yu H,  Oridonin, a novel lysine acetyltransferases inhibitor, inhibits proliferation and induces apoptosis in gastric cancer cells through p53- and caspase-3-mediated mechanisms.   Oncotarget.  2016  19;7(16):22623-31.  
    , Xu L, Jia RR, Wu Q, Wang T, Wei J, Ma JL, Shi M, Li ZS.   DDR2 Induces Gastric Cancer Cell Activities via Activating mTORC2 Signaling and Is Associated with Clinicopathological Characteristics of Gastric Cancer.   Dig Dis Sci.  2016  61(8):2272-83.  
    Shi M, Wei J, Meng WY, Wang N, Wang T,  Effects of phased joint intervention on Rho/ROCK expression levels in patients with portal hypertension.   Experimental and Therapeutic Medicine,  2016  12(3), 1618-1624. 
    Shi M, Wei J, Dong J, Meng W, Ma J, Wang T, Wang N,  Function of interleukin-17 and -35 in the blood of patients with hepatitis B-related liver cirrhosis.  Mol Med Rep.  2015  11(1):121-6. 
    Xu L, Wang T, Meng WY, Wei J, Ma JL, Shi M,  Salinomycin inhibits hepatocellular carcinoma cell invasion and migration through JNK/JunD pathway-mediated MMP9 expression.   Oncol Rep.  2015  33(3):1057-63. 
    , Xu L, Wang T, Wei J, Meng WY, Wang N, Shi M.   Givinostat inhibition of hepatic stellate cell proliferation and protein acetylation.   World J Gastroenterol.  2015  21;21(27):8326-39.  
    Wang F, Dai W,, Shen M, Chen K, Cheng P, Zhang Y, Wang C, Li J, Zheng Y, Lu J, Yang J, Zhu R, Zhang H, Zhou Y, Xu L, Guo C.   The synergistic in vitro and in vivo antitumor effect of combination therapy with salinomycin and 5-fluorouracil against hepatocellular carcinoma.   PLoS One.  2014  9(5):e97414 
    Dai W, Wang C, Wang F,, Shen M, Chen K, Cheng P, Zhang Y, Yang J, Zhu R, Zhang H, Li J, Zheng Y, Lu J, Zhou Y, Xu L, Guo C.   Anti-miR-197 inhibits migration in HCC cells by targeting KAI 1/CD82.  Biochem Biophys Res Commun.   2014  446(2):541-8. 
    Li GM,, Pan Q, Wang J, Fan JG, Sun C.  RNAi screening with shRNAs against histone methylation-related genes reveals determinants of sorafenib sensitivity in hepatocellular carcinoma cells.  Int J Clin Exp Pathol  2014  15;7(3):1085-92. 
    , Dong J, Meng W, Ma J, Wang N, Wei J, Shi M.   Effects of phased joint intervention on IL-35 and IL-17 expression levels in patients with portal hypertension.   Int J Mol Med.   2014  33(5):1131-9. 
    Ma J, Shi M, Li G, Wang N, Wei J, Wang T, Ma J,  Regulation of Id1 expression by epigallocatechin-3-gallate and its effect on the proliferation and apoptosis of poorly differentiated AGS gastric cancer cells.   Int J Oncol.   2013  43(4):1052-8. 
    , Wang N, Li GM, Fang WL, Wei J, Ma JL, Wang T, Shi M.   Mechanisms of trichostatin A inhibiting AGS proliferation and identification of lysine-acetylated proteins.   World J Gastroenterol  2013  19(21):3226-40. 
    , Fang WL, Wei J, Wang T, Wang N, Ma JL, Shi M.   The involvement of NLRX1 and NLRP3 in the development of nonalcoholic steatohepatitis in mice.  J Chin Med Assoc.  2013  76(12):686-92. 
    Wei J, Shi M, Wu WQ, Xu H, Wang T, Wang N, Ma JL,  IκB kinase-beta inhibitor attenuates hepatic fibrosis in mice.  World J Gastroenterol.   2011  17(47):5203-13. 
    , Shi M, Fu H, Xu H, Wei J, Wang T, Wang X.   Mammalian target of the rapamycin pathway is involved in non-alcoholic fatty liver disease.  Mol Med Rep.  2010  3(6):909-15.  
    , Shi M, Wang T, Shi T, Wei J, Wang N, Chen XM.  Signal transduction mechanism of TRB3 in rats with non-alcoholic fatty liver disease.  World J Gastroenterol.  2009  21;15(19):2329-35.